ICMR (International Center for Medical Research)

Verified siteinfoFast reply

Spain Calle De Cinca 21, 28002 Madrid, Spain

12 trials recruiting
Psoriasis · Dermatitis atopic · Hidradenitis
Adults and children

About Specializations

ICMR (International Center for Medical Research) in Madrid, Spain specialises in clinical trials of conditions such as Psoriasis, Dermatitis atopic, Hidradenitis, Alopecia areata, and other specialisations. This site conducts important research.

Main research areas of the site

Dermatological Diseases

The ICMR is a leading reference center in Spain and Europe dedicated to the research of inflammatory and/or immune-mediated dermatological diseases. Our main goal is to bring cutting-edge science to patients who have not found effective solutions through currently approved treatments. Whether you are a patient, a physician, or a pharmaceutical laboratory, we invite you to contact us for more information:

We research advanced solutions for different skin pathologies.
We conduct voluntary clinical trials at no cost to the patient.
We address complex cases that require innovative treatments.
We have a highly specialized team of professionals.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Calle De Cinca 2128002 MadridSpain

Open in maps ↗

Recruiting now: 12 trials
Conditions studied: 11
Partner status: Verified site

More sites in Madrid Spain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

27 clinical trials

Papulopustular rosacea

Recruiting

Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial

Investigational

Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Alopecia areata

Recruiting

A study to evaluate the effectiveness and safety of LAD603 in adults with severe to very severe alopecia areata

Investigational

A study to evaluate the effectiveness and safety of LAD603 in adults with severe to very severe alopecia areata

Investigational

Spain

Participants:18–64 years
Sponsor:Almirall S.A.

Contact Research Centre

Eczema nummular

Recruiting

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:Almirall S.A.

Contact Research Centre

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Palmoplantar pustulosis

Recruiting

A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis

Registered drug

A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Bimekizumab
Sponsor:UCB Biopharma

Contact Research Centre

Dermatitis atopic

Recruiting

Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

Investigational